About Dr. Ronald Matteotti, MBA
CEO of Trusted Telehealth®, Castle Connolly Top Doctor, Ai-Powered Cancer Care Innovator, Oncological Surgeon, and Global Telehealth Entrepreneur.
Dr. Ronald Matteotti, MBA is a globally recognized physician executive with a mission to transform cancer care. With over 25 years of experience in oncology and a background as a triple board-certified surgeon, he leads Trusted Telehealth® – www.tth.ai, with a commitment to precision, empathy, and digital access. His platform connects patients with top oncologists and ensures that expert second opinions, trial matching, and full-spectrum virtual support are available anywhere and at anytime in the world.
Reimagining Cancer Care Access with Trusted Telehealth®
Dr. Ronald Matteotti, MBA created Trusted Telehealth® – www.tth.ai to address a fundamental need: expert cancer care, accessible from anywhere and anytime. By combining AI tools with physician oversight, he has designed a platform where patients receive fast, evidence-based second opinions, backed by global oncology leaders. His vision is rooted in compassionate innovation, ensuring each patient receives personalized guidance and care beyond borders.
Leading with Empathy and Precision
Dr. Ronald Matteotti, MBA has led multidisciplinary cancer care teams across Europe, Asia, and the U.S. His approach to telehealth bridges traditional oncology with emerging AI solutions. Combining his deep clinical expertise with the strategic perspective of a Physician Executive MBA, Ronald creates a seamless experience where patients receive expert medical review, secure communication, and access to top specialists worldwide.
Ronald Matteotti’s Story
Dr. Ronald Matteotti, FACS, MBA earned his medical degree from the University of Basel in Switzerland and became one of the most respected oncological surgeons in Europe. His global exposure and entrepreneurial mindset led to the creation of Trusted Telehealth® – www.tth.ai, where he now focuses on transforming how patients and physicians collaborate in cancer treatment. With each case, he continues to bridge clinical excellence with digital innovation.